Company profile for Windtree Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Windtree Therapeutics Inc. is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. Windtree’s proprietary technology platform includes a synthetic, treatment peptide-containing surfactant (KL4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable non...
Windtree Therapeutics Inc. is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. Windtree’s proprietary technology platform includes a synthetic, treatment peptide-containing surfactant (KL4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized KL4 surfactant.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2600 Kelly Road, Suite 100 Warrington, PA 18976-3622
Telephone
Telephone
215-488-9300
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/17/3189210/0/en/Windtree-Therapeutics-Announces-It-May-Receive-License-Agreement-Payments-from-Its-Licensee-for-Renewed-Acute-Pulmonary-Development-by-the-Licensee.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/14/3188356/0/en/Windtree-Therapeutics-Announces-More-Strengthening-of-Its-Istaroxime-and-Next-Generation-SERCA2a-activator-Patent-Estate.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/11/13/3187721/0/en/Windtree-Therapeutics-Announces-It-Will-Receive-7-5-Million-In-Cash-and-Securities-from-the-Recently-Executed-Termination-Agreement-with-an-Environmental-Services-Company.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/09/02/3142749/0/en/Windtree-Therapeutics-Stockholders-Approve-Key-Proposals-for-Revenue-and-Profit-Generation-at-the-Special-Stockholder-Meeting.html

GLOBENEWSWIRE
02 Sep 2025

https://www.globenewswire.com/news-release/2025/08/11/3130951/0/en/Windtree-Announces-Istaroxime-has-been-Chosen-for-a-Plenary-Session-Presentation-at-the-Heart-Failure-Society-of-America-2025.html

GLOBENEWSWIRE
11 Aug 2025

https://www.globenewswire.com/news-release/2025/08/05/3127444/0/en/Windtree-Announces-Istaroxime-Phase-2-Interim-Analysis-in-SCAI-Stage-C-Cardiogenic-Shock-Patients.html

GLOBENEWSWIRE
05 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty